- NCIt
- C132146
Loading cancer entity…
Loading cancer entity…
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (101)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01822522 | Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2023 | clinicaltrials |
| NCT03237390 | Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT04800627 |
| Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor |
| terminated |
| Phase 1 / Phase 2 |
| 2 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Dec 27, 2022 |
| clinicaltrials |
| NCT05472220 | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | Dec 27, 2022 | clinicaltrials |
| NCT00909740 | A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | Genentech, Inc.INDUSTRY | 0 | Dec 12, 2022 | clinicaltrials |
| NCT05338957 | A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. | unknown | Phase 1 / Phase 2 | 30 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03792958 | Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 | 19 | AnewPharmaINDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT02252211 | Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers(LUD2014-002) | completed | Phase 1 | 9 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04765462 | Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | terminated | Phase 1 | 21 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT05508620 | A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors | unknown | Phase 1 | 270 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Aug 23, 2022 | clinicaltrials |
| NCT05478785 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 126 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT02227940 | Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 1 | 38 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05441046 | Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 | 120 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT03430882 | Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors | completed | Phase 1 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02451553 | Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer | completed | Phase 1 | 41 | University of WashingtonOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT05010096 | BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT02801097 | RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)(PAYLOAD) | terminated | Phase 1 | 28 | EpicentRx, Inc.INDUSTRY | 1 | May 17, 2022 | clinicaltrials |
| NCT03551795 | Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor | completed | Phase 1 / Phase 2 | 8 | Xiaoyan ZhangOTHER_GOV | 1 | May 9, 2022 | clinicaltrials |
| NCT02923466 | Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors | completed | Phase 1 | 76 | Vyriad, Inc.INDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT03254732 | Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers | terminated | Phase 1 | 33 | Polaris GroupINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05277454 | Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT | unknown | Phase 1 | 113 | Hutchison Medipharma LimitedINDUSTRY | 1 | Mar 14, 2022 | clinicaltrials |
| NCT01337505 | Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 24 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT04328506 | Bioequivalency Study of CM082 Tablet in Healthy Volunteers | completed | Phase 1 | 96 | AnewPharmaINDUSTRY | 1 | Nov 26, 2021 | clinicaltrials |
| NCT03662815 | Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor | unknown | Phase 1 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT04981691 | Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors(Amaretto) | unknown | Phase 1 | 12 | Ruijin HospitalOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | May 18, 2021 | clinicaltrials |
| NCT00452413 | A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer | completed | Phase 1 / Phase 2 | 65 | Eli Lilly and CompanyINDUSTRY | 1 | May 13, 2021 | clinicaltrials |
| NCT03009214 | A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours | completed | Phase 1 | 55 | amcure GmbHINDUSTRY | 2 | May 10, 2021 | clinicaltrials |
| NCT03205176 | AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | completed | Phase 1 | 49 | AstraZenecaINDUSTRY | 2 | May 6, 2021 | clinicaltrials |
| NCT01765790 | Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors | completed | Phase 1 | 68 | Baxalta now part of ShireINDUSTRY | 2 | May 5, 2021 | clinicaltrials |
| NCT04864379 | Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors | unknown | Phase 1 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04758897 | Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors | unknown | Phase 1 | 18 | CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY | 1 | Apr 27, 2021 | clinicaltrials |
| NCT02116777 | Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2021 | clinicaltrials |
| NCT01554371 | Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 44 | University of California, San FranciscoOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT03721679 | Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 | terminated | Phase 1 / Phase 2 | 7 | Oncovir, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02152943 | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | completed | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02902237 | tTF-NGR Phase I Study | completed | Phase 1 | 24 | University Hospital MuensterOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT04226066 | Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 69 | Tasly Tianjin Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 7, 2020 | clinicaltrials |
| NCT03291938 | IACS-010759 in Advanced Cancers | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03512340 | Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | completed | Phase 1 | 148 | Surface OncologyINDUSTRY | 2 | Oct 20, 2020 | clinicaltrials |
| NCT00836888 | ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan | completed | Phase 1 | 17 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03553108 | A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.(IVIVC) | completed | Phase 1 | 18 | AstraZenecaINDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT02857920 | Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 45 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT02323191 | A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors | completed | Phase 1 | 221 | Hoffmann-La RocheINDUSTRY | 4 | Aug 27, 2020 | clinicaltrials |
| NCT00939770 | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 / Phase 2 | 122 | Children's Oncology GroupNETWORK | 2 | Jun 9, 2020 | clinicaltrials |
| NCT02843204 | Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 110 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT04126668 | A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers | completed | Phase 1 | 24 | AnewPharmaINDUSTRY | 1 | May 21, 2020 | clinicaltrials |
| NCT02174172 | A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 158 | Hoffmann-La RocheINDUSTRY | 2 | May 12, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jan 10, 2023source: clinicaltrials